Do the New Data on Second-Generation Drug Eluting Stents Provide Reassurance on Safety, Efficacy, Even for Off-Label Use?
DOI:
https://doi.org/10.2015/hc.v5i1%20Sup.362Abstract
In in-stent restenosis, drug-eluting stents (DES) are superior compared with bare metal stents (BMS). However, there are concerns about safety because of the reports of increased risk of late and very late stent thrombosis. Stent thrombosis remains a major pitfall in contemporary percutaneous coronary intervention (PCI), leading to high rates of death and nonfatal myocardial infarction. After the US approval of the first two DES, the sirolimus-eluting stent (Cypher) in 2003 and paclitaxel-eluting stent (Taxus) in 2004, concern was raised about the safety of the devices due to the occurrence of late and very late stent thrombosis. Pooled analyses of available randomized trails at the time, however, showed similar rates of death and myocardial infarction in patients treated with one of these DES compared to the BMS counterpart in randomized clinical trials.... (excerpt)Downloads
Issue
Section
License
Authors who publish with this journal agree to the following terms:a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
